John C.K. Milligan IV

This profile gathers the share dealings of John C.K. Milligan IV in TherapeuticsMD, Inc., where the filings describe the role as chief executive. The record holds 52 filings, for trades running from 28 January 2014 to 11 May 2021.

On the open market, the record shows 4 purchases worth €425k and 24 sales worth €11.3M. Netting one side against the other leaves €10.9M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants and 18 option exercises. So far in 2021, the count stands at no purchases and 1 sale.

A typical purchase (the median) is worth €110k. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 3 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -6.0%. This is a record of the past, not a forecast.

The newest entry dates from 12 May 2021: an open-market sale of €38k, in TherapeuticsMD, Inc. The last insider purchase was made public on 29 October 2019, 2,567 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.